Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TVAX-028 in Chronic Hepatitis B
NCT07673068Phase 1Not yet recruiting
- Sponsor
- Grand Theravac Life Science (Nanjing) Co., Ltd.
- Start
- May 2026
- Primary completion
- May 2027
01
Overview
Phase 1, open-label trial of TVAX-028 in Chronic Hepatitis B (CHB) (4 arms), sponsored by Grand Theravac Life Science (Nanjing) Co., Ltd. Primary endpoints: Number of participants with adverse events at 60 weeks and Number of participants with dose-limiting toxicities at 60 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
TVAX-028
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07673068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07673068.